Barrick, Lyft, Nordstrom, Twitter and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 02/10/21
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/09/21
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical ProgramsBusiness Wire • 02/09/21
Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or RearrangementBusiness Wire • 01/29/21
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)Business Wire • 01/21/21
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for TafasitamabAccesswire • 01/12/21
Incyte (INCY) Partners With Cellenkos for Myelofibrosis TreatmentZacks Investment Research • 12/31/20
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804Business Wire • 12/30/20
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine StormBusiness Wire • 12/14/20
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of MedicinePRNewsWire • 12/11/20
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020Business Wire • 12/07/20
Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomasBusiness Wire • 12/07/20
Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host DiseaseBusiness Wire • 12/04/20
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19PRNewsWire • 11/19/20